Pharmacogenomics and adverse drug reactions

Shashi Amur, Issam Zineh, Darrell R. Abernethy, Shiew Mei Huang, Lawrence J. Lesko

Research output: Contribution to journalArticle

Abstract

Adverse drug reactions (ADRs) observed during drug development have been the cause for discontinuing development of many drugs. In addition, serious but rare ADRs observed after marketing have led to withdrawal of some drugs. A priori identification of individuals at risk of developing ADRs for a given drug will help develop strategies to reduce the risk for ADRs in these patients. US FDA initiatives and efforts at reducing ADRs to make drugs safer are described, including updating of drug labels to include genomic information intended to reduce ADRs. Pharmacogenomics can also be harnessed to identify individuals at risk of developing serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs that are traditionally considered unavoidable to avoidable ADRs.

Original languageEnglish (US)
Pages (from-to)633-642
Number of pages10
JournalPersonalized Medicine
Volume7
Issue number6
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Complementary Therapies
Marketing

Keywords

  • adverse drug reaction
  • CYP
  • drug label
  • drug safety
  • drug-metabolizing enzymes
  • genetic
  • genomic
  • polymorphism
  • variant

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Medicine(all)

Cite this

Amur, S., Zineh, I., Abernethy, D. R., Huang, S. M., & Lesko, L. J. (2010). Pharmacogenomics and adverse drug reactions. Personalized Medicine, 7(6), 633-642. https://doi.org/10.2217/pme.10.63

Pharmacogenomics and adverse drug reactions. / Amur, Shashi; Zineh, Issam; Abernethy, Darrell R.; Huang, Shiew Mei; Lesko, Lawrence J.

In: Personalized Medicine, Vol. 7, No. 6, 11.2010, p. 633-642.

Research output: Contribution to journalArticle

Amur, S, Zineh, I, Abernethy, DR, Huang, SM & Lesko, LJ 2010, 'Pharmacogenomics and adverse drug reactions', Personalized Medicine, vol. 7, no. 6, pp. 633-642. https://doi.org/10.2217/pme.10.63
Amur S, Zineh I, Abernethy DR, Huang SM, Lesko LJ. Pharmacogenomics and adverse drug reactions. Personalized Medicine. 2010 Nov;7(6):633-642. https://doi.org/10.2217/pme.10.63
Amur, Shashi ; Zineh, Issam ; Abernethy, Darrell R. ; Huang, Shiew Mei ; Lesko, Lawrence J. / Pharmacogenomics and adverse drug reactions. In: Personalized Medicine. 2010 ; Vol. 7, No. 6. pp. 633-642.
@article{1d817719c714433d9669ffba3114f049,
title = "Pharmacogenomics and adverse drug reactions",
abstract = "Adverse drug reactions (ADRs) observed during drug development have been the cause for discontinuing development of many drugs. In addition, serious but rare ADRs observed after marketing have led to withdrawal of some drugs. A priori identification of individuals at risk of developing ADRs for a given drug will help develop strategies to reduce the risk for ADRs in these patients. US FDA initiatives and efforts at reducing ADRs to make drugs safer are described, including updating of drug labels to include genomic information intended to reduce ADRs. Pharmacogenomics can also be harnessed to identify individuals at risk of developing serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs that are traditionally considered unavoidable to avoidable ADRs.",
keywords = "adverse drug reaction, CYP, drug label, drug safety, drug-metabolizing enzymes, genetic, genomic, polymorphism, variant",
author = "Shashi Amur and Issam Zineh and Abernethy, {Darrell R.} and Huang, {Shiew Mei} and Lesko, {Lawrence J.}",
year = "2010",
month = "11",
doi = "10.2217/pme.10.63",
language = "English (US)",
volume = "7",
pages = "633--642",
journal = "Personalized Medicine",
issn = "1741-0541",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Pharmacogenomics and adverse drug reactions

AU - Amur, Shashi

AU - Zineh, Issam

AU - Abernethy, Darrell R.

AU - Huang, Shiew Mei

AU - Lesko, Lawrence J.

PY - 2010/11

Y1 - 2010/11

N2 - Adverse drug reactions (ADRs) observed during drug development have been the cause for discontinuing development of many drugs. In addition, serious but rare ADRs observed after marketing have led to withdrawal of some drugs. A priori identification of individuals at risk of developing ADRs for a given drug will help develop strategies to reduce the risk for ADRs in these patients. US FDA initiatives and efforts at reducing ADRs to make drugs safer are described, including updating of drug labels to include genomic information intended to reduce ADRs. Pharmacogenomics can also be harnessed to identify individuals at risk of developing serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs that are traditionally considered unavoidable to avoidable ADRs.

AB - Adverse drug reactions (ADRs) observed during drug development have been the cause for discontinuing development of many drugs. In addition, serious but rare ADRs observed after marketing have led to withdrawal of some drugs. A priori identification of individuals at risk of developing ADRs for a given drug will help develop strategies to reduce the risk for ADRs in these patients. US FDA initiatives and efforts at reducing ADRs to make drugs safer are described, including updating of drug labels to include genomic information intended to reduce ADRs. Pharmacogenomics can also be harnessed to identify individuals at risk of developing serious ADRs and to treat these individuals with alternative therapy, thus converting ADRs that are traditionally considered unavoidable to avoidable ADRs.

KW - adverse drug reaction

KW - CYP

KW - drug label

KW - drug safety

KW - drug-metabolizing enzymes

KW - genetic

KW - genomic

KW - polymorphism

KW - variant

UR - http://www.scopus.com/inward/record.url?scp=78649995976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649995976&partnerID=8YFLogxK

U2 - 10.2217/pme.10.63

DO - 10.2217/pme.10.63

M3 - Article

AN - SCOPUS:78649995976

VL - 7

SP - 633

EP - 642

JO - Personalized Medicine

JF - Personalized Medicine

SN - 1741-0541

IS - 6

ER -